# GPT 5.2 Review - Reviewer 2/3 (Parallel)

**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** medium
**Timestamp:** 2026-01-28T15:38:45.672783
**Review mode:** Parallel (3 independent reviewers)
**Response ID:** resp_03d9f0af7a54a38500697a1ecdb95c8190bb94915129b61a61
**Tokens:** 6500 in / 6634 out
**Response SHA256:** 5c8cd1e8b4c4552a

---

## Referee Report: “Telehealth Parity Laws and Depression Diagnosis Prevalence: Evidence from Staggered State Adoption” (Jan 28, 2026)

This paper asks whether state telehealth parity laws increased access to mental health care, using BRFSS state-year “ever diagnosed with depression” prevalence (2011–2019) and a staggered-adoption DiD design estimated with Callaway & Sant’Anna (2021). The headline result is a precisely-estimated null: ATT ≈ −0.48 pp (SE 0.35).

The question is policy-relevant, and the author uses a modern staggered-DiD estimator rather than naive TWFE. However, in its current form the paper is not close to publishable in a top general-interest journal or AEJ:EP because (i) the outcome is poorly matched to the mechanism (a slow-moving lifetime stock), (ii) treatment is coded too coarsely relative to large legal heterogeneity and implementation timing, (iii) identification is under-argued (and key threats are not addressed with credible tests/design upgrades), and (iv) the presentation is far too short and reads like a technical memo rather than an AER/QJE/JPE/ReStud/Ecta paper.

Below I detail format problems, inference/methodology, identification, literature gaps, writing quality, and concrete steps that could make the project publishable.

---

# 1. FORMAT CHECK

### Length
- **Fails top-journal norms.** The PDF excerpt shows **~13 pages total** (ending at p.13 with references starting around p.11–13). Top general-interest journals typically require substantially more development (conceptual framing, institutional detail, data validation, robustness, mechanisms, heterogeneity, etc.). Your own paper ends before it has done that.

### References / bibliography coverage
- **Insufficient for the question.** The bibliography is short and largely generic. It cites key DiD papers (Callaway–Sant’Anna; Goodman-Bacon; de Chaisemartin–D’Haultfoeuille) and a few telehealth descriptives. It does **not** adequately cover:
  - telehealth parity law measurement and heterogeneity,
  - pre-COVID tele-mental-health utilization evidence (beyond one Medicare rural paper),
  - BRFSS measurement issues (2011 redesign) and implications for time-series comparability,
  - modern DiD inference and diagnostics (Sun–Abraham, Borusyak–Jaravel–Spiess, Roth et al. diagnostics, etc.),
  - related empirical evaluations of telehealth reimbursement/coverage expansions.

### Prose vs bullets
- Mostly paragraph-form, but there are **multiple bullet lists** in institutional background and discussion (e.g., §2.3; §6). Bullet lists are fine for definitions/robustness menus, but here they substitute for deeper narrative and argument. AER/QJE/JPE expect sustained prose with evidence and citations.

### Section depth
- Several major sections do **not** have 3+ substantive paragraphs:
  - §2 “Institutional Background” is short and partly bullets.
  - §3 “Data” is thin: very limited validation, no discussion of BRFSS comparability, weighting, aggregation, or measurement error.
  - §5 “Results” is mostly tables plus brief interpretation; mechanism/heterogeneity are underdeveloped.

### Figures
- Figure 1 appears to have axes and confidence bands. However:
  - The event-study figure is not accompanied by the underlying coefficient table.
  - It is not clear whether the figure is publication quality (font sizes, legibility) and whether the plotted coefficients are comparable across changing composition/weighting.

### Tables
- Tables contain real numbers and SEs. No placeholders. Good.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### (a) Standard errors
- **Pass (mostly).** Main ATT has an SE; cohort ATTs have SEs; TWFE comparison has SEs.

**But**: A top-journal referee will still require:
- SEs (or CIs) reported for **all** event-time coefficients (not just shown visually).
- Clear statement of the bootstrap procedure: number of replications, resampling scheme, and whether inference is valid with **51 clusters** (and only **27 treated states contributing to identification**).

### (b) Significance testing
- **Pass.** p-values and significance are reported.

### (c) Confidence intervals
- **Pass** for main result (95% CI in Table 3). Event-study has pointwise bands.

**Issue**: You use **pointwise** bands. For DiD event studies, readers often want **uniform/simultaneous confidence bands** or at least a **pre-trend joint test** (and discussion of power against plausible violations).

### (d) Sample sizes
- **Pass** at a high level (N=458 state-years). But it is not enough:
  - If you used BRFSS microdata to create state-year estimates, the effective sample size varies dramatically by state-year. That variation affects precision and potentially identification (precision-weighting, survey design). The paper currently treats each state-year equally.
  - You should report the number of respondents underlying each state-year (or at least summary quantiles) and whether estimates are survey-weighted.

### (e) DiD with staggered adoption
- **Pass on estimator choice.** You use Callaway–Sant’Anna with not-yet-treated controls and present TWFE only as comparison. That is the right direction.

**However, a “pass” for top journals requires more than naming C&S**:
- You must show cohort-time ATTs in an appendix table, explain negative weights issues you avoid, and demonstrate robustness to alternative modern estimators (Sun–Abraham interaction-weighted event study; Borusyak–Jaravel–Spiess imputation; de Chaisemartin–D’Haultfoeuille robust aggregations).
- Inference with staggered adoption is delicate; a top journal expects multiple triangulations.

### (f) RDD
- Not applicable.

**Bottom line on methodology:** The paper is *not unpublishable due to inference*, but it is far from “top-journal-ready” on implementation transparency, diagnostics, and robustness expected for staggered DiD.

---

# 3. IDENTIFICATION STRATEGY

### Credibility of identification
The identifying assumption is that, absent parity laws, treated and control states would have similar trends in lifetime depression diagnosis prevalence. You provide an event study with near-zero pre-trends, which is helpful.

But for a policy like telehealth parity, **endogenous adoption is a first-order concern**:
- States may adopt parity laws alongside broader mental-health initiatives, insurance reforms, Medicaid policies, broadband investments, or provider licensing changes.
- Adoption timing may correlate with urbanization, insurer market structure, or pre-existing telehealth capacity—all of which can affect diagnosis trends.

### Key assumption discussion
- Parallel trends is mentioned (§4.1) and visually assessed (§5.2). However:
  - No **formal pre-trend joint test** is reported.
  - No evidence is provided on **comparability of treated vs controls** (levels, covariates, pre-trends by subgroup).
  - No discussion of **anticipation effects** (providers or insurers preparing before the “in effect for full calendar year” date).

### Placebos and robustness
You include a few robustness checks (dropping late adopters; never-treated only). This is not close to what top journals expect.

Missing robustness/placebos that are particularly important here:
1. **Policy-placebo outcomes**: outcomes plausibly unaffected by telehealth parity (e.g., arthritis diagnosis; height; flu shot?—choose carefully). This checks whether adoption correlates with general survey reporting/health awareness changes.
2. **Event-study using alternative estimators** (Sun–Abraham; imputation).
3. **Leave-one-state-out** and **influence diagnostics**, especially because cohort heterogeneity table shows “significant” effects driven by **single-state cohorts** (2017 cohort has 1 state; 2019 cohort has 1 state). That is a red flag: one-state “significance” is very likely picking up idiosyncratic shocks.
4. **Alternative treatment timing**: effective date vs enactment date; partial-year coding; sensitivity to coding “treated” in enactment year vs following year.
5. **Controls for concurrent policies**: at minimum, Medicaid expansion timing, state mental health parity enforcement, scope-of-practice changes, psychologist prescribing authority, broadband expansion, and opioid policy shocks.

### Do conclusions follow from evidence?
You conclude “telehealth parity laws alone may have had limited effects” (Abstract/Conclusion). That is plausible, but the evidence is not strong enough to support that policy conclusion because:
- The **outcome is a lifetime stock**; even meaningful access improvements may not move it detectably over 1–5 years.
- The treatment is **not the same policy across states**; pooling could average positive effects (payment parity, broad modality) with near-zero effects (coverage-only, narrow modality), producing a misleading null.
- ERISA preemption is invoked as an explanation, but it is not tested empirically.

### Limitations
You discuss several limitations (§6), which is good, but they remain **speculative** because the paper does not empirically adjudicate among them.

---

# 4. LITERATURE (MISSING REFERENCES + BibTeX)

## (i) DiD / staggered adoption: missing modern applied guidance
You cite C&S, Goodman-Bacon, de Chaisemartin & D’Haultfoeuille. For a top journal, you should also engage:

1) **Sun & Abraham (2021)** (interaction-weighted event studies; negative weighting issues)
```bibtex
@article{SunAbraham2021,
  author  = {Sun, Liyang and Abraham, Sarah},
  title   = {Estimating Dynamic Treatment Effects in Event Studies with Heterogeneous Treatment Effects},
  journal = {Journal of Econometrics},
  year    = {2021},
  volume  = {225},
  number  = {2},
  pages   = {175--199}
}
```

2) **Sant’Anna & Zhao (2020)** (doubly robust DiD; you mention “doubly robust” but do not cite the foundational paper)
```bibtex
@article{SantAnnaZhao2020,
  author  = {Sant'Anna, Pedro H. C. and Zhao, Jun},
  title   = {Doubly Robust Difference-in-Differences Estimators},
  journal = {Journal of Econometrics},
  year    = {2020},
  volume  = {219},
  number  = {1},
  pages   = {101--122}
}
```

3) **Inference with clustered errors** (important with 51 clusters and staggered design)
```bibtex
@article{CameronGelbachMiller2008,
  author  = {Cameron, A. Colin and Gelbach, Jonah B. and Miller, Douglas L.},
  title   = {Bootstrap-Based Improvements for Inference with Clustered Errors},
  journal = {Review of Economics and Statistics},
  year    = {2008},
  volume  = {90},
  number  = {3},
  pages   = {414--427}
}
```

(If you use wild cluster bootstrap specifically, cite the relevant wild-bootstrap references as well.)

## (ii) BRFSS comparability / 2011 redesign (major measurement issue you ignore)
BRFSS changed weighting and sampling in 2011 (cell phones; raking), creating level shifts that complicate trend analyses. You start in 2011, which helps, but you should still document comparability and whether the depression question series is stable.

A commonly cited CDC methodological reference:
```bibtex
@article{Pierannunzi2012,
  author  = {Pierannunzi, Carol and Hu, Shaohua S. and Balluz, Lina},
  title   = {A Systematic Review of Publications Assessing Reliability and Validity of the Behavioral Risk Factor Surveillance System (BRFSS), 2004--2011},
  journal = {BMC Medical Research Methodology},
  year    = {2013},
  volume  = {13},
  pages   = {49}
}
```
(If you have a more specific CDC/BRFSS redesign technical report, cite that too; the key is to demonstrate you understand the measurement environment.)

## (iii) Telehealth utilization and policy background (thin and somewhat dated)
You cite Barnett et al. (2018) and Mehrotra et al. (2017). You should add foundational telemedicine background and evidence on pre-COVID telehealth growth and demand. For example:
```bibtex
@article{UscherPinesMehrotra2014,
  author  = {Uscher-Pines, Lori and Mehrotra, Ateev},
  title   = {Analysis of Direct-to-Consumer Telemedicine for Acute Care},
  journal = {Health Affairs},
  year    = {2014},
  volume  = {33},
  number  = {2},
  pages   = {258--264}
}
```

More importantly, you must engage any credible empirical work that evaluates **telehealth parity laws specifically** (coverage parity vs payment parity; modality restrictions). The current draft cites policy trackers (CCHPCA, NCSL) but not peer-reviewed causal evaluations. If such evaluations exist (and I strongly suspect they do), failing to cite them is disqualifying for AEJ:EP/top-5.

---

# 5. WRITING QUALITY (CRITICAL)

### Prose vs bullets
- Several parts read like an outline (notably §2.3 and parts of §6). This is not fatal, but top journals expect stronger narrative writing and integration of institutional details with the empirical design.

### Narrative flow
- The introduction is competent but generic. It does not deliver a sharp “why now / why this paper” hook beyond telehealth is important and parity laws exist.
- The paper does not clearly articulate a conceptual framework mapping **parity law → reimbursement → provider supply/telehealth offering → utilization → diagnosis** and where the chain may break. Without that, the null result is hard to interpret.

### Sentence/paragraph craft
- Many paragraphs are “topic sentences + citations” without a distinctive contribution. The discussion section reads as plausible speculation rather than evidence-based explanation.

### Accessibility and magnitudes
- You report the ATT in percentage points, which is good. But you should contextualize: e.g., relative to baseline 19% prevalence, −0.48 pp is about −2.5% of the mean. Also discuss what magnitude would be plausible given diagnosis flows.

### Figures/tables as standalone objects
- Tables are mostly interpretable. But Figure 1 needs:
  - explicit sample size/cohorts used,
  - whether bands are pointwise or uniform,
  - a table of coefficients/SEs in appendix.

**Overall writing diagnosis:** This reads like a careful class project / internal memo rather than a top-journal paper. Top outlets require a more compelling story, stronger institutional grounding, and far more empirical validation.

---

# 6. CONSTRUCTIVE SUGGESTIONS (HOW TO MAKE THIS PUBLISHABLE)

### A. Fix the outcome: your main dependent variable is poorly matched to the policy
“Ever told you have depression” is a **lifetime stock**. Over 2011–2019, it will move slowly and reflect long-run cohort composition, diagnostic norms, antidepressant marketing history, etc. Telehealth parity plausibly affects:
- **visits**, **therapy starts**, **follow-up adherence**, **medication management**, **wait times**, and possibly **new diagnoses** (a flow), not the cumulative lifetime stock.

**Actionable alternatives** (any one would strengthen the paper massively):
1. Use BRFSS measures closer to flows or current mental health: *number of poor mental health days*, K6 (if available), or past-year treatment (if available in BRFSS modules).
2. Use **claims/EHR-based outcomes** (MarketScan, Optum, Medicare, Medicaid T-MSIS) to measure:
   - tele-mental-health visit rates,
   - new depression diagnoses,
   - psychotherapy initiation and continuity,
   - antidepressant initiation.
3. If you insist on “diagnosis prevalence,” use a design that models the **diagnosis hazard** (new diagnosis) rather than the lifetime stock.

### B. Measure treatment properly: parity laws vary enormously
Coding “parity law in effect” as a binary variable is likely too crude. You need to code:
- coverage parity vs payment parity,
- modality restrictions (video-only vs includes audio-only; store-and-forward),
- eligible originating sites / patient location constraints (pre-COVID often restrictive),
- mental health inclusion/exclusion,
- enforcement strength.

Then estimate heterogeneous effects by policy “bite.” A pooled null with large heterogeneity is not informative.

### C. Address ERISA preemption empirically (not just as a story)
You claim limited bite because self-insured plans are exempt. Test it:
- Use outcomes among populations more likely in fully insured plans vs self-insured (by firm size/industry proxies) if you move to micro/claims data.
- Triple differences: fully-insured vs self-insured; states with parity vs not; pre/post.
- Alternatively, focus on **individual market** or **small-group market**, where state mandates matter more.

### D. Strengthen identification and diagnostics
Minimum expected by top journals for staggered policy DiD:
- Show results under **Sun–Abraham** and **imputation** estimators.
- Provide **formal pre-trend tests** and sensitivity (e.g., Roth-style sensitivity to violations / “honest DiD” style bounds).
- Include **state-specific linear trends** as a sensitivity check (with discussion of pros/cons).
- Rich covariate adjustments and/or reweighting to improve comparability.
- Explicit accounting for concurrent policies and shocks (Medicaid expansion, opioid epidemic intensity, mental health workforce expansions, broadband).

### E. Fix the cohort “significance” problem
Table 4 flags “significant” effects for cohorts with **one state** (2017 and 2019). This is not a credible heterogeneity finding; it screams “idiosyncratic shock.” At minimum:
- show state-specific event studies for those states,
- do leave-one-out aggregation,
- report cohort sizes and discuss fragility.

### F. Expand the sample period (if defensible) and justify why not
You state the outcome panel begins in 2011. If the depression question exists earlier (it likely does), you should explore extending pre-period to:
- include “always-treated” states with pre data,
- increase power for pre-trend assessment,
- separate long-run secular trends from treatment effects.

If you cannot extend earlier because of measurement discontinuities, explain that carefully and show robustness around the redesign.

### G. Reframe contribution for general-interest readership
For AEJ:EP/top-5, “parity laws had a null effect on a stock self-report diagnosis measure” is not enough. A publishable contribution would look like:
- “Payment parity drove tele-mental-health supply but not access for the uninsured,” or
- “ERISA preemption explains why state mandates failed; effects concentrated in small-group market,” or
- “Parity increased utilization but shifted diagnoses across settings (substitution), no net increase.”

That requires better data and sharper mechanisms.

---

# 7. OVERALL ASSESSMENT

### Strengths
- Policy question is important and timely (telehealth regulation).
- Uses an appropriate modern staggered-adoption DiD estimator rather than naive TWFE.
- Reports SEs, CIs, and sample sizes for main tables.
- Transparently notes that always-treated states do not identify effects in the chosen window.

### Critical weaknesses
- **Outcome mismatch** (lifetime depression diagnosis is a slow-moving stock; likely incapable of capturing access changes).
- **Treatment mismeasurement** (binary parity indicator ignores crucial legal heterogeneity and implementation).
- **Identification not persuasive enough** for endogenous adoption; robustness/placebos are far below top-journal standards.
- **Cohort heterogeneity claims are not credible** when “significant” cohorts contain one state.
- **Paper is far too short** and reads like a memo; institutional detail, data validation, and design transparency are insufficient.
- Literature positioning is incomplete; important modern DiD and domain-policy work is missing.

### Specific improvements (highest priority)
1. Switch to utilization/flow outcomes (claims preferred) and measure tele-mental-health directly.
2. Recode parity laws in a granular way (payment vs coverage; modalities; mental health scope).
3. Add stronger identification checks: alternative estimators, pre-trend tests, leave-one-out, placebo outcomes, concurrent policy controls.
4. Expand paper substantially: institutional details, data appendix, measurement validation, heterogeneity/mechanisms.

---

DECISION: REJECT AND RESUBMIT